Peer Review #2 of "Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer (v0.1)" Article Swipe
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.7287/peerj.11528v0.1/reviews/2
· OA: W4210307941
Background: MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients.Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis.Methods: BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases.Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results:The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ± 0.55 versus 0.07 ± 0.48, respectively, p<0.001) as well as in lung cancer patients with stage I-IIA disease than in those with stage IIB-IV disease (0.98 ± 0.64 versus 0.66 ± 0.54, respectively, p<0.05).Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822.ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I-IIA adenocarcinoma.Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.
